BRAFi molecules including vemurafenib and dabrafenib as the second line of monotherapy in BRAF-mutant NSCLC showed an ORR of 33–42% and median PFS of 5.5–7.3 months. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.